Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Matching geography

Reports matching your search in:
 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!
 

Vaccines: market research reports

1594

A vaccine is a preparation used to prevent contraction of a particular disease by triggering an immune response to that disease. Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements during the 20th century. However, risks are associated with using all immunobiologics, and no vaccine is 100% safe or effective.

Key issues in the global vaccine market today include product safety, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems.

The topic of vaccine safety became prominent during the mid 1970’s with increases in lawsuits filed on behalf of those presumably injured by the diphtheria, pertussis, and tetanus (DPT) vaccine. To respond to public health concerns, Congress passed the National Childhood Vaccine Injury Act (NCVIA) in 1986, which in turn led to the creation of the National Vaccine Program Office (NVPO) within the Department of Health and Human Services (DHHS). NCVIA requires that all healthcare providers who administer vaccines containing diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, hepatitis B, Haemophilus influenzae type b and varicella provide a Vaccine Information Statement (VIS) to the vaccine recipient, their parent or legal guardian prior to each dose. Each VIS contains a brief description of the disease as well as the risks and benefits of the vaccine. The NCVIA also mandated that all healthcare providers report certain adverse events that occur following vaccination. As a result, the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink Project (VSD) were established in 1990. VAERS provides a mechanism for the collection and analysis of adverse events associated with vaccines currently licensed in the U.S.; VSD involved forming partnerships with four large health maintenance organizations (HMOs) to continually monitor vaccine safety. The National Vaccine Injury Compensation Program, which was also created by NCVIA, compensates those individuals who have been injured by vaccines on a no-fault basis. On a global basis, the World Health Organization (WHO) is actively involved in ensuring the quality of vaccines.

RSS Feeds

Vaccines market research reports and industry analysis

< prev 1  2  3  4  5  6  7  8  9  10  next >
Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...  |  more...
$5,175.00
Triple Analysis: Prostate Cancer, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...  |  more...
$5,175.00
Triple Analysis: Apoptosis, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area ...  |  more...
$5,175.00
Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area ...  |  more...
$5,175.00
Triple Analysis: Breast Cancer, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...  |  more...
$5,175.00
Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...  |  more...
$5,175.00
Triple Analysis: Melanoma, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area ...  |  more...
$5,175.00
Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...  |  more...
$5,175.00
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides
1/7/2013 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...  |  more...
$5,175.00
Triple Analysis: Lymphoma, Cancer Vaccines and Peptides
1/7/2013 | published by: BioSeeker Group AB
... to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area ...  |  more...
$5,175.00
Triple Analysis: Cancer Vaccines, Antibodies and Peptides
1/7/2013 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
The Next Wave In Cancer Treatment - Kinase Inhibitors
12/4/2012 | published by: Kalorama Information
... a focus of cancer profiled in this report, including: Breast Colorectal Head/Neck Kidney Leukemia Liver Lung Melanoma Ovarian Pancreatic Prostate Stomach The report covers both currently marketed and late stage development kinase inhibitors for cancer ...  |  more...
$2,500.00
Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis
12/3/2012 | published by: Renub Research
... than US$ 23 Billion by 2015 growing with a single digit CAGR during 2012 – 2015. This incremental growth has been due to blockbuster vaccines (Prevnar7, Prevnar 13, Rotarix and Rotateq) sales in Billion of ...  |  more...
$1,400.00
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
12/1/2012 | published by: La Merie Publishing
... (HSV) type 1 and/or type 2 and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the ...  |  more...
$396.00
EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
11/30/2012 | published by: GlobalData
... been shown to reduce influenza morbidity and mortality and high economic burden associated with influenza illness. GlobalData’s epidemiologists expect seasonal influenza vaccination coverage rates for all countries but the UK and China to remain constant ...  |  more...
$6,995.00
PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$6,995.00
Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent ...  |  more...
$6,995.00
PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
Fluzone (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
Fluarix (Seasonal Influenza Vaccine) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
< prev 1  2  3  4  5  6  7  8  9  10  next >